Question 1

What is the BPC-157 peptide?

Accepted Answer

BPC-157 is a laboratory-made copy of a fragment found in human gastric juice. Chemically it is a pentadecapeptide, meaning a chain of 15 amino acids. A 2025 patent review describes it as a pentadecapeptide isolated from human gastric juice. A 2025 narrative review instead calls it a synthetic pentadecapeptide originally isolated from gastric juice: one presents a fragment found in the body, the other something built in a laboratory. The 2003 rat tendon paper gives the sequence as GEPPPGKPADDAGLV, with a molecular weight of 1419. No source among the research behind this page calls it a hormone, and the reviews group it with the wound-healing peptides rather than with anything hormonal.

Question 2

Is BPC-157 a peptide hormone?

Accepted Answer

No — the reviews that catalogue these compounds keep BPC-157 away from the hormonal ones. A 2026 orthopaedic review sorts peptides by what they are thought to do, and groups BPC-157 with the wound-healing peptides, alongside TB-500 (a synthetic fragment of thymosin β4) and GHK-Cu (copper tripeptide-1). Its other group is the growth hormone secretagogues — ipamorelin, CJC-1295, tesamorelin — meaning compounds that make a gland release its own hormone. A 2026 review of peptides in ageing sorts them the same way, splitting tissue repair (BPC-157, TB-500) from growth hormone modulation (CJC-1295, ipamorelin). One finding does brush the hormone system: the 2025 systematic review reports that BPC-157 enhances growth hormone receptor expression, which is the receptor rather than the hormone. More places for a signal to land is not more signal, and no study among the research behind this page has measured a hormone level in a person given BPC-157.

Question 3

Do BPC-157 peptides actually work?

Accepted Answer

The fullest answer is the 2025 systematic review, which kept 36 studies. In preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries. That is a real animal signal, across four tissue types. The one clinical entry is thinner than that count suggests. A 2026 review describes a single human case series reported improvements in pain after intra-articular knee injections of BPC-157, meaning injections into the joint itself. It notes that a lack of controls limit its applicability and reliability. A 2025 review finds scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides. Most of the studies were done in small rodents. Only a handful of research groups have looked at this peptide in depth. Findings count for more when separate groups produce them, so this work is concentrated rather than replicated. A 2026 review also raises the placebo effect as something that could be driving the result.

Question 4

What organs does BPC-157 heal?

Accepted Answer

Every entry on the tissue list here is an animal or laboratory model. A 2018 review reports that BPC 157 was consistently effective in all of the models of acute or chronic injury of esophagus, stomach, duodenum and lower gastrointestinal tract. A 2021 review extends that to deep burns, diabetic ulcers, and alkali burns, and then to tendon, ligament, muscle, bone, nerve, spinal cord, cornea and blood vessels. A compound reported as effective everywhere is either acting on something very general or being studied by one small group using one method. The reviews argue for the first, calling BPC 157 a native cytoprotection mediator: a signal that keeps cells intact under stress. The second fits the fact that only a handful of research groups have performed in-depth studies regarding this peptide, and the animal work does not tell you which is right.

Question 5

What happens to your body when you take BPC-157?

Accepted Answer

Almost everything on record happened inside an injured animal, which limits what this answer can be. The 2025 systematic review gives the broad preclinical account: BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines. Angiogenesis is new blood vessel growth, and every measurement behind that sentence came from an animal or a dish. A 2026 rat experiment shows how narrow the uninjured case remains. Twenty-four male Wistar albino rats were randomized into four groups (n = 6): SHAM, B (BPC 157 only), IR (I/R), and IRB (I/R + BPC 157), so exactly one of those groups got the compound with nothing wrong with them, and that group is six animals. In people the nearest answer is an absence: in the 12-woman cystitis pilot, no one dropped out of the study, and no adverse events were reported. Twelve women across a single procedure is a record of what did not happen, rather than a description of what does.

Question 6

Does BPC-157 make you gain weight?

Accepted Answer

No study among the research behind this page has measured body weight or body composition in a person given BPC-157 — not in the cystitis pilot, not in the knee review, and nowhere in the animal work. Two nearby findings get borrowed, and both say less than they look. The first is one line in a 2025 orthopaedic review, which credits the animal work with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair — a review listing metabolism among four items, with no number attached to any of them. The second points the other way. In the 2003 rat tendon study the peptide presented with no effect on the growth of cultured cell of its own, and did something only when a growth inhibitor was in the dish, turning that inhibition into growth in cultured tendon cells. Restoring growth that something else had suppressed and adding mass to a healthy body are different questions, and the second has not been asked.

Question 7

Has BPC-157 been tested in people?

Accepted Answer

Three times, and the three are not equivalent. The strongest is a 2024 pilot in interstitial cystitis, a bladder pain condition the authors call a disabling disease with no effective treatment. Twelve women between the ages of 39 and 76 years took part at a private clinic, none of whom had responded to pentosan polysulfate, an approved treatment for interstitial cystitis. Complete resolution of symptoms after one treatment was reported in 10 of 12 patients; it was planned in advance, enrolled prospectively, and had no control group. The knee study is weaker, and is regularly quoted as though it were not: a 1-year chart review from 2019 to 2020 was performed at a single clinic, and of the 17 patients in the study, 16 were contacted by phone six months to a year after the injection, so what got recorded was recollection. No specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living. That is a chart review with a telephone survey attached, rather than a pilot, and the distinction is the whole point. The third was never an efficacy question: a 2025 narrative review lists it as intravenous safety/pharmacokinetics — how quickly the body takes up and clears a compound. BPC 157 for Acute Hamstring Muscle Strain Repair is a Phase 2 study listed as RECRUITING, and it has not reported. What each of those three reports can and cannot establish on its own is weighed at the BPC-157 results page.

Question 8

Does BPC-157 work immediately?

Accepted Answer

Two clocks run through this literature and are easy to confuse: how long the peptide lasts, and how long the tissue takes to change. On the first, the 2025 systematic review gives a half-life of less than 30 minutes, so the compound leaves the circulation quickly. On the second, the animal outcomes are read in days, because the 2003 rat Achilles experiment took its biomechanical, microscopical and macroscopical assessment on day 1, 4, 7, 10 and 14. Human timing is unmeasured. The cystitis pilot reported complete resolution of symptoms after one treatment in 10 of 12 patients, scored on a questionnaire that records an impression rather than a date. The knee survey asked patients, months afterwards, to recall the length of time the peptides helped ease the pain. Neither design can establish an onset.

Question 9

How long does BPC-157 last in the system?

Accepted Answer

Two clocks answer this, and running them together causes most of the confusion. The first is clearance: the 2025 systematic review reports that BPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys. A half-life is how long the amount in the blood takes to fall by half, so the molecule itself is largely gone within a few hours, which is the route out rather than what it does to either organ; the measurement underneath is thin, since a 2025 orthopaedic review calls the work beneath it very early in vivo research on pharmacokinetics, and no study among the research behind this page has repeated it in people under controlled conditions. The second clock is how long any effect lasts, and it is not the same clock: the systematic review's reading of the knee chart review is that 7 of 12 patients reported relief for >6 months, recalled by telephone months afterwards with nothing to compare against. A compound gone from the blood inside an hour and a benefit remembered half a year later cannot both be measuring the same thing, and only the first has been measured.

Question 10

What happens when you stop taking BPC-157?

Accepted Answer

No study among the research behind this page has followed a person after stopping BPC-157, and the designs on record could not have caught it if there were something to catch. In the 2003 rat Achilles experiment, doses were firstly applied at 30 min after surgery, the last application at 24 h before autopsy, and the animals were assessed and then killed; nowhere in that design is there a window in which a rat is alive, off the compound, and still being watched. The human studies have the same hole: the cystitis pilot gave the peptide around the area of inflammation of the bladder during a single procedure, so its whole finding is already a post-course one, taken from twelve women who were on nothing when they were asked. What is left is a gap rather than a reassurance: nothing on record describes a rebound or a loss of whatever was gained, and nothing rules those out either, because no study among the research behind this page has been built to look. The 2019 review notes only that there are few studies reporting any adverse reactions to the administration of BPC 157 — a note about what got written down, not what got looked for.

Question 11

Does oral BPC-157 actually work?

Accepted Answer

Every human study of BPC-157 used a needle. The three covered knee pain, interstitial cystitis, and a study of how fast the body takes up and clears the compound. No study among the research behind this page tested an oral route in a person. The route claim comes from the animal work, and it is striking. A 2018 review states that BPC 157 was consistently effective across gastrointestinal injury models given intraperitoneally, per-orally or locally, which means into the abdominal cavity, by mouth, or at the site of damage. A 2022 review describes it given intraperitoneally or in drinking water or topically, at the site of injury. Take that seriously, then look at its shape. Route-independence is unusual, it is reported almost entirely by one research group, and it was measured in rodents with damaged guts rather than people with intact ones.

Question 12

What is the legal status of BPC-157?

Accepted Answer

Not approved anywhere — and the reason matters more than the word. A 2025 literature and patent review states that BPC-157 has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans. Read the end of that sentence: no regulator weighed a case and turned it down; none was handed one. The 2024 cystitis pilot records the same: BPC-157 is currently not approved by the US Food and Drug Administration. The word the reviews use for that state is investigational, and a 2025 narrative review puts it plainly: until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. Investigational describes something still being studied, rather than something cleared for a stated use. The material used in the only prospective human study was BPC-157 manufactured by a 503A compounding pharmacy — a fact about who made a batch, not an approval of what was in it. The FDA's recall record for compounded injections is set out on the safety page.

Question 13

Is BPC-157 safe?

Accepted Answer

No study among the research behind this page measures safety in a person taking BPC-157 over any length of time. The 2025 systematic review that searched this literature reached the same conclusion and said so plainly: no clinical safety data were found. The animal record is reassuring as far as it goes — preclinical safety studies showed no adverse effects across several organ systems — but it was collected in rats, over weeks, by researchers who knew exactly what was in the vial. Only three pilot studies have examined BPC-157 in humans, and none of them was controlled. Read the animal record for what it is. No adverse effects across several organ systems, in rats, over weeks, tells you the compound did not visibly damage those animals in that window. It does not tell you what months of use does to a person, and it was never designed to. A reader who wants the organ-by-organ version of this — liver, heart, kidneys, interactions, daily use, and the six FDA recalls of compounded BPC-157 injections — should start at the BPC-157 safety page.

Question 14

How does BPC-157 work?

Accepted Answer

The short version: BPC-157 is described as a cytoprotective signal, something that keeps cells intact while an injury repairs, rather than a growth factor that builds tissue. The molecular account comes mainly from a 2025 narrative review. It reports VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis. Those promote angiogenesis, which is new blood vessel growth, plus fibroblast activity and neuromuscular stabilization, in animal models. The peptide also engages ERK1/2 signaling and exerts anti-inflammatory effects. A 2021 review adds the step underneath: BPC 157 rapidly increases various genes expression in rat excision skin wound. Standard healing proteins are held back by in vivo instability and reliance on carriers. BPC 157 instead improves tendon, ligament and bone healing using same regimens like in gastrointestinal healing studies, in the rat models reviewed. Whether that breadth is real biology or an artefact of one group's method is the open question.

BPC-157